CIK 0001393434 · Large accelerated filer
OCULAR THERAPEUTIX, INC
Sign in to watch- Ticker
- OCUL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 781-357-4000
- Business address
- 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
- Former names
- I-THERAPEUTIX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $799,174
- in 9 filings, $788K under 10b5-1 plans
Net −$799,174. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-10 | Robins Jason Shand Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +14,024 | 14,024 | ||
| 2026-06-10 | Hong Seung Suh Director | Grant or award | +14,000 | 60,933 | ||
| 2026-06-10 | Hong Seung Suh Director | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2026-06-10 | LINDSTROM RICHARD L MD Director | Grant or award | +14,000 | 260,933 | ||
| 2026-06-10 | LINDSTROM RICHARD L MD Director | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2026-06-10 | RAINES MERILEE Director | Grant or award | +14,000 | 60,933 | ||
| 2026-06-10 | RAINES MERILEE Director | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2026-06-10 | Williams Leslie J. Director | Grant or award | +14,000 | 65,433 | ||
| 2026-06-10 | Williams Leslie J. Director | Grant or award · Stock Option (Right to Buy) | +44,000 | 44,000 | ||
| 2026-06-03 | Waheed Nadia Chief Medical Officer | Sale 10b5-1 | −14,828 | $8.27 | $123K | 300,079 |
| 2026-05-28 | Dugel Pravin See Remarks | Gift 10b5-1 | −394,696 | 0 | ||
| 2026-05-28 | Dugel Pravin See Remarks | Gift 10b5-1 | +394,696 | 694,811 | ||
| 2026-05-26 | Dugel Pravin See Remarks | Sale 10b5-1 | −21,156 | $8.20 | $173K | 2,597,170 |
| 2026-05-26 | Kaiser Peter Chief Development Officer | Sale 10b5-1 | −2,967 | $8.20 | $24K | 266,141 |
| 2026-05-26 | Heier Jeffrey S. Chief Scientific Officer | Sale 10b5-1 | −3,018 | $8.20 | $25K | 320,350 |
| 2026-05-26 | Nayak Sanjay Chief Strategy Officer | Sale 10b5-1 | −1,858 | $8.20 | $15K | 328,795 |
| 2026-04-09 | Dugel Pravin See Remarks | Gift | −394,696 | 2,618,326 | ||
| 2026-04-09 | Dugel Pravin See Remarks | Gift | +394,696 | 394,696 | ||
| 2026-02-23 | Dugel Pravin See Remarks | Sale 10b5-1 | −20,056 | $8.28 | $166K | 3,013,022 |
| 2026-02-23 | Kaiser Peter Chief Development Officer | Sale 10b5-1 | −2,810 | $8.28 | $23K | 269,108 |
Page 2 of 8 · 158 trades